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Abstract

Children with oppositional defiant disorder (ODD) and a concurrent Axis I diagnosis are often
prescribed drug therapy for attention deficit hyperactivity disorder (ADHD) to manage disruptive
behavior. However, ODD symptoms tend to be poorly controlled, raising questions about the
effectiveness of drug therapy in children with the condition. Safety and long term consequences
of pharmacological agents for ODD are important factors clinicians must consider before
initiating treatment. The purpose of this literature review is to examine the pharmacodynamics
and efficacy of drug therapy used for ODD in school-age children and adolescents. Additionally,
awareness of poor behavior patterns and recognition of symptoms associated with ODD in
children among health care providers was explored. A literature review exploring ODD and drug
therapy for ODD and related behavioral disorders was conducted from various online databases.
Results from 15 reviewed studies suggest that pharmacologic therapy is typically prescribed for
ODD symptoms when a comorbid condition such as ADHD, a mood disorder, or an anxiety
disorder is present. Drug therapy for ADHD has demonstrated effective behavioral outcomes in
reducing ODD symptom severity in children and tolerable side effects when used for short-term
therapy. Studies have demonstrated success and better control of ODD symptoms with a focused
drug therapy regimen. Overall, the benefits of drug therapy can potentially outweigh the risks of
adverse effects, and improve the quality of life in children with ODD. In conclusion, uncovering
the reasons for poorly controlled ODD in children can be of clinical significance to health care
providers and can support decision making when considering drug therapy for children with this
condition.
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Introduction
Oppositional defiant disorder (ODD) affects young children through the adolescent age
and is characterized by aggressive behavior, rebelliousness toward authority, and poor anger
control. Due to the nature of symptoms, ODD creates poor psychosocial interactions across the
lifespan including, unhealthy relationships with family members, friends, school teachers, and
additional authority figures.
Oppositional defiant disorder is diagnosed using the Diagnostic and Statistical Manual of
Mental Disorders, 4th ed. (DSM-IV). The diagnosis of ODD in children is conducted by
observing a pattern of behaviors that must be displayed for at least six months and include at
least four of the following: often loses temper, often argues with adults, often actively defies or
refuses to comply with adults’ requests or rules, often deliberately annoys people, often blames
others for his or her mistakes or misbehaviors, is often touchy or easily annoyed by others, is
often angry or resentful, and is often spiteful or vindictive (Hamilton & Armando, 2008).
Furthermore, the behavior must cause significant impairment in social, academic, or
occupational functioning; must occur independently of other mental disorders; and must not meet
the criteria for conduct disorder or antisocial personality disorder if the client is over the age of
18 (Hamilton & Armando, 2008). Diagnosis of ODD can be problematic since health care
providers must differentiate between typical childhood misbehavior and actual disruptive
conduct. In addition, ODD is often accompanied by comorbid mental health conditions such as
attention deficit hyperactivity disorder (ADHD) or mood disorder, which further complicate
diagnoses.
The cause of ODD is unknown, however researchers believe there are environmental,
biologic, and genetic influences that contribute to its etiology. Environmental factors include but
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are not limited to, parental overreaction to behavior at a young age, lower socioeconomic status,
and maternal depression (Harvey, Metcalfe, Herbert, & Fanton, 2011). Furthermore, research
suggests decreased sensitivity to hormones and catecholamine’s such as, cortisol, epinephrine,
and norepinephrine, occurs with ODD and alters the child’s response to punishment.
Impairments in the frontal lobe and cingulate cortex may contribute to lack of motivation,
sensitivity to reward for positive behavior, and impulse and emotional control (Matthys,
Vanderschuren, & Schutter, 2013). Due to the evidence of chemical and hormonal imbalances,
drug therapy is utilized as a treatment option to control behavior of children living with ODD.
Since ODD and ADHD are often comorbid conditions, ADHD agents are commonly prescribed
to control symptoms of both conditions. However, the effectiveness, safety, and maintenance
abilities of ADHD agents on ODD symptom severity reduction is still being examined.
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Problem
Behavioral therapy is the first line of treatment for ODD including interventions at the
child and parent levels. Behavioral therapy alone is not always effective when a comorbid
disorder is present. Therefore, pharmacologic treatment is initiated as an alternative method to
manage ODD symptoms. A plethora of pharmacologic agents are used for ODD treatment
including, stimulants (Ritalin, Concerta, Aderall), selective norepinephrine reuptake inhibitors
(Atomoxetine), mood stabilizers, antidepressants, and antipsychotics (Smith & Coghill, 2010). A
major problem concerning drug therapy in children with ODD arises due to the lack of research
and knowledge surrounding safety, efficacy, and long-term success of treatment with ADHD
drugs on children and adolescent’s ODD symptoms. The pharmacodynamics and
pharmacokinetics are poorly understood in children as well. The presence of comorbid
conditions such as ADHD, depression, or anxiety with ODD influences the choice and
effectiveness of pharmacological agents. ODD can be difficult to diagnose which can lead to
poor management. Nurses have the opportunity to intervene at the elementary school by raising
awareness regarding ODD symptoms and increasing knowledge about risk factors that can
hinder early recognition of the illness.
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Purpose
The purpose of this literature review was to explore the effectiveness of ADHD
pharmacologic agents used to manage ODD. The focus was on whether pharmacologic agents
used for ODD are safe, effective, and have long-term sustainability of symptom control on
children and adolescents. Emphasis was placed on the pharmacokinetics and pharmacodynamics
of prescribed medicines (for ODD) in adolescents. The secondary purpose was to address issues
with poor control of ODD symptoms. The literature review discussed the role of school nurses
and existing education gaps. Several subtopics related to poor management of ODD including
lack of knowledge among parents, frequent comorbid conditions, and broad diagnosis criteria we
researched as well.
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Methods
Research was obtained from EBSCO which collected articles from a variety of databases
including CINAHL, ERIC, MEDLINE, PsycARTICLES, PsycBOOKS, PsycINFO, and
Academic Search Premier. To narrow the results, limitations were set to full text, peer reviewed,
written in the English language, subject age of 6 to 17, publication date from 2000 – 2013, and
human focused. For CINAHL specifically, an additional inclusion was met for any author that
was a nurse. ODD and medications were used as inclusion criteria, while demographics and
behavioral therapy were used as exclusion criteria. The search yielded 638 articles. With the
addition of the key search terms medication* and children*, 172 studies were remaining. The
articles were reviewed and chosen based relevance to pharmacologic treatments for ODD and the
disease process. 30 total articles were utilized in the literature review. For the table of articles, 40
were eliminated for not being peer reviewed clinical trials or not focusing on one medication. An
additional four were excluded for not focusing on an ADHD medication specifically, leaving a
total of six articles for analysis. The six articles selected were all randomized, double-blind,
placebo-controlled clinical trials. A supplemental search was done in EBSCO involving ODD,
nursing, and treatment to obtain information about the nurses role in management. Lastly, a
search was done outside of the EBSCO database to find articles related to the diagnosis of ODD.
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Background
Prevalence of ODD and ADHD Comorbidity
According to the Diagnostic and Statistical Manual of Mental Disorders (4th ed., text
rev.; DSM-IV-TR; American Psychiatric Association, 2000) ODD effects about 2 – 16 % of the
general population. Before puberty ODD is more common in males however after puberty,
prevalence is equal among sexes. Lastly, about half of the children with ADHD have ODD as
well (4th ed., text-rev.; DSM-IV-TR; American Psychiatric Association, 2000).
Brief Description of Scales Used to Measure ADHD and ODD Symptom Severity
A variety of scales are used to quantify ADHD and ODD symptoms. From knowledge
the researcher knows the scales are either parent, teacher, or clinician rated.
ADHD Rating Scale, Version IV (ADHD-RS-IV)
The ADHD-RS-IV (DuPaul, Power, Anastopoulos, & Reid, 1998), based on diagnostic
criteria from the DSM-IV, is an 18-item scale consisting of two subscales: inattention and
hyperactivity. There is a parent questionnaire and a teacher questionnaire focusing on symptom
frequency over six months to assess treatment response in children and adolescents with ADHD
(Goodman et al., 2010).
Conners’ Parent Rating Scale – Revised: Short Form (CPRS-R:S)
The CPRS-R: S (Conners, 1997) has 27 items and is used to assess ADHD symptoms
such as inattention, hyperactivity/impulsivity, learning problems, executive functioning,
aggression, peer relations, and family relations. The scale evaluates oppositonal behavior as well.
Swanson, Nolan, & Pelham Rating Scale IV (SNAP-IV)
The SNAP-IV (Swanson, 1992) evaluates ADHD, ODD, and additional psychiatric
disorders that occur in childhood. Inattention, hyperactivity/impulsivity, and DSM-IV criteria for
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ODD are subscale focus areas. The SNAP-IV is used in clinical trials to measure the efficacy of
ADHD treament (Bussing et al., 2008).
Clinical Global Impressions Scale (CGI)
The CGI scale (Guy, 1976), is used by researchers to measure global functioning of an
individual before and after medication treatment. There are two components of the scale to
measure severity (CGI-S) and improvement (CGI-I) (Busner & Targum, 2007). According to
Busner & Targum (2007) the CGI scale summerizes, “patient history, psychosocial
circumstances, symptoms, behavior, and the impact of the symptoms on the patient’s ability to
function”.
Child Health Questionnaire (CHQ)
The CHQ (Landegraf, Abetz, & Ware, 1996) is utilized by researchers to evaluate the
influence of health issues on a child’s functioning and well-being (Waters, Salmon, & Wake,
2000). The CHQ is not specific to ADHD or ODD but can be used to assess any illness during
childhood.
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Review of Literature
Atomoxetine Studies
An eight week, randomized, double-blind, placebo study was conducted on children ages
8 – 18 with ADHD and with or without comorbid ODD (Newcorn, Spencer, Biederman, Milton,
& Michelson, 2005). Of 293 subjects, 115 had ODD and 178 did not. Tools to measure the
effectiveness of atomoxetine on symptom management included, the ADHD-RS-IV-Parent
verson, CPRS-R: S, CGI-S, and a parent questionnaire. Results showed that atomoxetine was
more effective than the placebo in decreasing ADHD and ODD symptoms. ADHD children with
comorbid ODD needed a higher dose of 1.8 mg/kg/day to see results. Children with only ADHD
showed improvement with only 1.2 mg/kg/day (Newcorn, et al., 2005). Using the CHQ
Psychosocial Summary scale, quality of life was assessed. Improvements were seen in
individuals with and without ODD however, subjects with ODD had lower scores at baseline.
The findings showed that children with ADHD and comorbid ODD exhibit a decrease in
functioning compared to children with only ADHD. (Newcorn et al., 2005). Adverse effects
were described to be typical of atomoxetine and significance was not discussed.
An eight week, multi-site, randomnized, placebo-controlled trial was done on children
ages 6 – 15 with ADHD and comorbid ODD. The purpose was to measure the efficacy of
atomoxetine on 137 children that failed to improve in a six week psychological, parent training
program (Dell'Agnello et al., 2009). Various rating scales were used by the researchers and
parents to measure the efficacy of atomoxetine. Results revealed that atomoxetine improved
ADHD and ODD symptoms, especially inattention, hyperactivity, and oppostional behavior.
Best results were seen with atomoxetine and concurrent psychotherapy for the parent and child.
As for safety, 45.8% of children on atomextine complained of nausea, vomiting, and abdominal
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pain while 43.0% complained of anorexia. Additonal adverse effects with atomextine included
somnolence (29.9%), headache (21.5%), influenza (8.4%), nervosuness (6.5%), and insomnia
(4.7%). Only three participants withdrew from the trial because of adverse events (Dell’Agnello,
et al., 2009). The study results showed atomoxetine was effective and tolerated well.
An additional study examined the effectiveness of atomoxetine in controlling ODD and
ADHD symtoms (Bangs et al., 2008). The researchers conducted an eight week study consisting
of 131 children, ages 6 – 12, who were randomly chosen to receive 1.2 mg/kg/day of
atomoxetine or a placebo. Efficacy was measured using the SNAP-IV ODD total scores. There
was a significant decrease in ODD symptom severity with the atomoxetine treated group at
weeks two and five, however no noticed improvement at week eight. ADHD symptom severity
decreased through the entire study. As for safety, atomoxetine was well tolerated. Some adverse
effects were seen more when compared to the placebo group. For example, atomoxetine subjects
reported decreased appetites (24.4%), nausea (20.5%), and fatigue (17.3%) as compared to 1.4%,
8.6%, and 5.7% for the placebo group. Diastolic blood pressures were increased (9.7% increased
5 mm HG or more above the 95th percentile) and weights decreased (3.5% from baseline) in the
atomoxetine group (Bangs, et al., 2008).
Researchers analyzed 98 children from two similar studies involving atomoxetine versus
a placebo in ADHD children with comorbid ODD (Kaplan et al., 2004). The studies examined
the efficacy and safety of atomoxetine in children ages 7 – 13. Both studies were double-blind,
randomized, placebo-controlled trials. Efficacy was measured utilizing the ADHD-RS-IV and
through interviews with the parents and children. Researchers found automoxetine to be very
effective in reducing ADHD symptoms, but not ODD symptoms when compared to the placebo
group. The medication was very well tolerated and only caused minimal adverse effects such as
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decrease in appetite and emotional lability. Of the 98 participants, one dropped out because of
hostility and two others withdrew because of nervousness (Kaplan et al., 2004).
Hazell et al. (2006) conducted a randomized, double-blind, placebo-controlled study to
examine the influence of comorbid ODD on relapse of symptoms during nine months of
treatment with atomoxetine for ADHD. The research was a continuation of a 10 week
atomoxetine trial for subjects that responded well to treatment. Dosages of the 10 week trial
ranged from 0.5 mg/kg/day to 1.8 mg/kg/day of atomoxetine. To progess in the open-label trial,
participants had to achieve at least a 25% reduction from baseline data on the ADHD RS total
score. Consequently, successful participants were ages 6 – 15 and were randomly chosen to
either continue receiving atomoxetine or switch to a placebo. Of 416, 292 continued with
atomoxetine and 124 received placebo. 17% of patients with ODD and ADHD relapsed while
26% of patients with ADHD without ODD relapsed during the study. In the study, atomoxetine
treatment was effective in preventing relapse of symptoms and even benefited patients that
relapsed anyway. For example, of all relapsed patients, the ones on atomoxetine benefited longer
than the ones that received the placebo (Hazell et al., 2006). Although the study did not focus on
ODD symptoms specifically, results showed that atomoxetine is effective for treatment of
ADHD with comorbid ODD over a longer period of time.
Non Peer Reviewed Clinical Trials
Dittman et al. (2011) completed a nine week, randomized, placebo-controlled, doubleblind on 180 children (ages 6 – 17) diagnosed with ADHD and comorbid ODD. The purpose
was to examine the effectiveness of atomoxetine and to compare fast versus slow titration. The
preferred dose was 1.2 mg/kg/day. Results showed a significant decrease of ADHD and ODD
symptoms with atomoxetine. In regards to safety, adverse effects such as fatigue, sleep disorders,
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nausea, and gastrointestinal issues were seen in 60.0% of the fast titrated group and in 44.3% of
the slow titrated group (Dittman, et al., 2011). Slowly increasing the medication dose was better
tolerated.To summarize, atomoxetine was effective in reducing ADHD and ODD symptoms and
relatively safely.
Wehmeier et al. (2011) conducted a randomized, placebo-controlled, double-blind, nine
week study to observe the effects of atomoxetine on quality of life (QOL) in children ages 6-17
with ADHD and comorbid ODD or conduct disorder (CD). The dose of atomoxetine was started
low at 0.5 mg/kg and titrated either fast or slow to a target dose of 1.2 mg/kg. Although the main
focus of the research was QOL, safety and effectiveness was examined weekly for the first three
weeks and then bi-weekly until the ninth week. Results were measured through the use of the
SNAP-IV and additional behavioral scales. Reseachers found the use of atomoxetine to be more
successful at reducing ADHD, ODD, and CD symptoms compared to the placebo. There was no
significant difference in the fast or slow titrated groups. For safety, more than 10% of
participants and at least one member in each sub-group (fast titrated, slow titrated, and placebo)
experienced adverse effects. Fatigue, nausea, headache, vomiting, upper abdominal pain, and
anorexia were reported the most (Wehmeier et al., 2011).

Clonidine in Combination with a Psychotimulant Study
Hazell and Stuart (2003) studied the use of clonidine in combination with a
psychostimulant to decrease hyperactivity and aggression in children with ADHD combined with
ODD or CD. The six week, single blind trial consisted of 60 participants ages 6 – 14 that had
been treated for less than three months with methylphenidate or dexamphetamine. Subjects were
randomly assigned to receive a 0.10 mg morning and evening dose of clonidine or a placebo.
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Using the CPRS-R: S to gauge results, the clonidine-treated participants yielded better results
compared to the placebo group. For example, 57% of the subjects that received clonidine had
scores decrease more than 38% on the rating scale as compared with a 21% decrease in the
placebo group. As an added benefit, clonidine helped in decreasing side effects from the
concurrent psychotropic medications. There were expected adverse effects in the clonidine
treated group including dizziness and drowsiness but only in the early stages of the trial. The
results of the study suggest that clonidine works well as an adjunct with a psychostimulant in
decreasing ADHD and ODD or CD symptoms.

Mixed Amphetamine Salts Extended Release (MAS XR) (Adderall XR) Study
Spencer et al. (2006) conducted a four week, multicenter, randomized, double-blind,
parallel-group, placebo-controlled, forced-dose-escalation study. Before the study began, there
was a one to four week period where all psychotropic medications were discontinued and a
placebo was administered. After the discontinuation, there were 308 participants ranging from
ages 6-17, randomly chosen to receive either 10, 20, 30, or 40 mg/d of MAS XR or a placebo.
All 308 participants were diagnosed with ODD but only 244 had comorbid ADHD. Efficacy was
measured using ODD portions of the SNAP-IV parent and teacher rating. Participants and
parents also attended regular check-up visits in order for researches to collect data regarding
safety. The data included recording reported adverse effects and observing trends in vital signs,
12-lead electrocardiograohic (ECG) findings, laboratory results, and physical examinations.
Results showed the largest decrease in symptoms with the MAS XR 30 and 40 mg/d groups in
particpants with and without comorbid ADHD. Regarding safety, adverse affects were reported
more often from the MAS XR including decreased appetite (25.3%), insomnia (19.5%),
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headache (18.5%), and abdominal pain (10.7%). Weight loss ranged from 1.1 – 3.5 pounds in the
MAS XR group as compared to no weight loss in the placebo group.

Immediate Release Methylphenidate Study
A two week study consisting of 31 children ages 6 – 12 was conducted to observe the
effectiveness of methylphenidate in controlling ODD symptoms. All participants had ODD,
ADHD, and either Tourette’s or chronic multiple tic disorder (Gadow, Nolan, Sverd, Sprafkin, &
Schneider, 2008). Under double-blind conditions, subjects were given placebo and three doses of
methylphenidate (Novartis Brand Ritalin-IR 0.1 mg/kg, 0.3 mg/kg, and 0.5 mg/kg) administered
twice daily. Efficacy was measured by one physician observation and computer vigilance testing
every two weeks, at a clinic. Parents and teachers completed rating scales two times per week
throughout the entire study as well (Gadow et al., 2008). Although there were differences
between parent and teacher ratings, improvement of ODD symptoms were seen with
methylphenidate as compared to the placebo. In reference to safety, the higher the dosage of
methylphenidate, the higher the adverse effects. For example, parents rated physical complaints
higher with the methylphenidate dosages. There was a directly proportional relationship between
higher methylphenidate dosages and higher heart rates and systolic blood pressures as well
(Gadow, et al., 2008).
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Discussion
Efficacy of ADHD agents
Ten articles were reviewed and four ADHD medications were observed for efficacy in
controlling ODD symptoms. The medications included atomoxetine, clonidine, MAS XR
(Aderrall XR), and methylphenidate. Overall, the four medications were relatively effective in
reducing ODD symptom severity.
Of the ten studies reviewed, six dicussed aotomoxetine. The atomoxetine clinical trials,
with the exception one, showed a greater decrease in ODD symptoms with medication compared
to a placebo. Bangs et al. (2008) found that overall, atomoxetine reduced ODD symptoms and
while there was progression throughout the study, there was no significant improvement noted
over the last three weeks. The effective dosage of atomoxetine varied amongst studies. Dittman
et al. (2011), Wehmeier et al. (2011), and Bangs et al. (2008) found 1.2 mg/kg/day to be
effective in decreasing disruptive behaviors. On the other hand, Newcorn et al. (2005) found 1.2
mg/kg/day of atomoextine sufficient to help ADHD, however individuals with comorbid ODD
showed improvements at 1.8 mg/kg/day. Dell’Agnello et al. (2009) used a range of atomoxetine
dosages (0.85 – 1.33 mg/kg/day) for ADHD patients with and without comorbid ODD. There
was no specification made on whether the comorbid ODD patients required higher dosages.
Lastly, one study observed children taking atomoxetine over nine months and results showed an
overall prevention of relapse of ODD symptoms (Hazell et al., 2006). Thus atomoxetine must be
titrated to reach an effective dosage which should be individualized to each patient.
Clonidine in combination with either methlyphenidate or dexamphetamine showed to be
effective in treating ODD symptoms (Hazell & Stuart, 2003). However, due to the small sample
size more research is warranted. In regards to MAS XR, larger doses were needed to yield
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desirable results in ODD management (Spencer et al., 2006). Lastly,the methylphenidate dosages
produced reduced ODD symptom severity (Gadow et al., 2008).

Safety of ADHD agents
ADHD pharmacologic agents are often well tolerated in children and adolescents because
of the short half-lives of the medications. The most common adverse effects seen with
atomoxetine included anorexia/decreased appetites, nausea, vomiting, fatigue, abdominal pain,
sleep disorders, and decrease in body weight. One study had three participants discontinue due to
adverse effects and observed less growth in height over the course of the trial (Dell’Agnello et
al., 2009). MAS XR had similar adverse effects as atomoxetine including decreased appetite,
weight loss, headache, insomnia, and abdominal pain (Spencer et al. 2006). Clonidine caused
mostly dizziness and drowsiness which were expected. An interesting unexpected but postive
effect of clonidine was a decrease in undesirable effects of concurrent psychotropic medications
(Hazell & Stuart, 2003). Clonidine acts on central alpha receptors which decreases heart rate and
blood pressure, hence the sedative effects. Lastly the immediate release methylphenidate, a
commonly prescribed stimulant, casued an increase in heart rate and systolic blood pressure
(Gadow et al., 2008).

Previous Broad Diagnosis Criteria and DSM-V
Broad diagnosis criteria made ODD difficult to identify. Symptoms had to be present
over a period of six months, however frequency was not specified in the DSM-IV criteria. The
DSM-IV stated the word, “often” in the symptom list which left interpretation up to the
healthcare provider (Keenan, 2012). With no methods to measure and gauge ODD symptoms,
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diagnosis was difficult in differentiating between normal childhood misconduct and truly
disruptive behavior. Contrastly, the DSM-V criteria has been made more specific in hopes of
creating an easier diagnosis process. Symptoms have been placed into three groups including,
angry/irritable mood, argumentative/defiant behavior, and vindictiveness. Exclusion critera for
CD has been removed as well (American Psychiatric Association, 2013). Frequency of
symptoms have been defined to address the issue of differentiating between normal childhood
behavior and true signs of the disorder. Lastly, since ODD affects children and families across
the lifespan, a severity rating has been added to gauge the extensiveness of the illness (American
Psychiatric Association, 2013). Many of the issues with broad diagnosis criteria have been
addressed in the DSM-V criteria. Providers now have an improved, proficient method to
correctly diagnosing ODD.

Information for school nurses
School nurses should be familiar with the presentation of ODD symptoms. Indications of
ODD include but are not limited to, refusal to follow commands from adults, easily annoyed by
others, hostility, verbally aggressive tendencies, spiteful behavior, stubborness, and inability to
maintain healthy relationships with peers (Kledzik, Thorne, Prasad, Hayes, & Hines, 2012). A
child with such widespread behavioral issues will most likely be known by various teachers and
school staff. School nurses can be more effective when equipped with the knowledge to
recognize ODD symptoms and intervene to assist with initiation of treatment. Early intervention
is important because untreated ODD will steadily progress and cause greater problems later in
life (Pardini & Fite, 2010). School nurses can play a huge role in treatment teams by helping to
improve academic performance and assisting with the patient’s relationships with family and
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friends (Barcalow, 2006). School nurses can be actively involved with facilitating and observing
a child’s progression in treatment.
School nurses should be knowledgeable about all treatment options for students,
including drug therapy, and what adverse effects to expect. Teachers and school nurses are often
great sources of information when attempting to measure the efficacy of drug treatment in the
shool setting.

Implications
ODD affects 2 – 16 % of children and causes problems across the life span (4th ed., textrev.; DSM-IV-TR; American Psychiatric Association, 2000). Control of symptoms is important
for quality of life for the child and family because ODD has been linked to later criminal charges
and lifelong conduct problems (Pardini & Fite, 2010). Early recognition, diagnosis, and
effective and safe treatment are imperative to prevent future issues for affected children and
adolescents. Pardini and Fite (2010) stated that ADHD symptoms worsen ODD and CD
symptoms over time. The commonality of comorbid conditions with ODD, especially ADHD,
further stresses the importance of knowledge of effective drug therapies. Although best results
are seen with psychotherapy and drug therapy for ODD with comorbid disorders, more
psychiatrisits and primary care physicians are solely using the drug therapy route (Harpaz-Rotem
& Rosenheck, 2006). Healthcare providers should be educated on the most effective and safe
drug therapy options in order to develop adequate treatment plans for patients. Extensive
experiementation with several drugs on young children to find the right combination can become
unethical and potentially dangerous. Lastly, nurses should know the presentation of ODD
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(common signs and symptoms), how to effectively react to disruptive behavior, and what
resources are available to the affected clients and families to facilitate child improvement.
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Conclusions
All of the articles synthesized suggest that ADHD agents are generally effective in
controlling ODD symptoms and are relatively safe in school-age children. Adverse effects from
drug therapy in children with ODD are present with all types of drug therapy and ODD symptom
control has shown that the risks outweigh the benefits in this population. Drug therapy in
combination with psychotherapy for both the parent and child has been shown to be a very
effective form of treatment. School nurses can play a huge role in intervening and providing
resources for treatment in order to prevent progression of oppositonal behavior. Healthcare
providers collaborating with families and their chidren with ODD and having knowldege of the
most effective and safe options can allow for an increase in quality of life for patients and
families.

19

Limitations
Six atomoxetine clinical trials were found which suggests effectiveness for the drug,
however other ADHD agents are not as well researched in regards to ODD symptom control. Of
the atomoxetine trials, two were not peer reviewed therefore while the articles were supportive of
the effectiveness of atomoxetine in ODD symptom control, they were not approved by experts
before publishing. The two non peer reviewed were not listed in the table of articles and the
researcher found an adequate amount of peer reviewed atomoxetine studies to support
conclusions. Only three additional clinical trails studying three different stimulants were found
and critiqued. Although the three trials showed effectiveness in reducing ODD symptoms,
further studies would have to be done for results to be generalizable to a larger population.
Lastly, only one trial was found that studied the effectiveness of atomoxeitine over a matter of
nine months. More research must be conducted to examine the sustainability of positive effects
from ADHD agents in ODD symptom control.
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Further research
Additonal research needs to be conducted to further examine the effectiveness of
clonidine, MAS XR, and immediate release methylphenidate on controlling ODD symptoms. An
additional study should be inititated investigating provider awareness of ODD symptoms and
treatment to gauge education needs and increase knowledge among healthcare workers.
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Appendix A: Table of Evidence
Duration Drug and Mean Inclusion Criteria (age
Efficacy and Safety
Daily Dose
range)

Study
(Author,
Date,
Journal)
Newcorn et
8 weeks
al., (2005).
Journal of
the American
Academy of
Child &
Adolescent
Psychiatry,
44(3), 240248. doi:
10.1097/000
0458320050300000008
Dell’Agnello 8 weeks
et al., (2009).
European
Neuropsycho
pharmacolog
y, 19(11),
822-834. doi:
10.1016/j.eur
oneuro.2009.
07.008

Atomoxetine
-0.5 mg/kg/day
(n=44)
-1.2 mg/kg/day
(n=83)
-1.8 mg/kg/day
(n=85)

Atomoxetine
-Mean starting
dose: 0.61 ±
0.08 mg/kg/day
(0.44-0.80)
-Mean titrated
dose: 1.10 ±
0.13 mg/kg/day
(0.85-1.33)

293 subjects
-8 – 18
-Normal intelligence (IQ
≥80)
-Diagnosed with ADHD
with or without comorbid
ODD according to DSMIV criteria
-Attention
Deficit/Hyperactivity
Disorder Rating ScaleIV-Parent version,
investigator-administered
and –scored scale ≥1.5
SDs above age and
gender normals
137 subjects
-6 – 15
-Diagnosed with ADHD
and ODD based on DSMIV criteria
-Score ≥ 1.5 SD above
age normal for ADHD
subscale of SNAP-IV
-SNAP-IV ODD subscale
score of at least 15
-CGI-S ≥4
-IQ ≥ 70
22

Limitations

-Subjects with ADHD
and ODD showed most
improvements at 1.8
mg/kg/day
-Subjects without ODD
showed significant
improvement at 1.2
mg/kg/day
-Individuals with
ADHD and comorbid
ODD may need higher
dosages of atomoxetine
to achieve desired
effects

-Efficacy of
atomoxetine in
controlling ODD
symptoms was the
secondary purpose of
the study
-Separating the
subjects into smaller
groups decreased the
validity of the study
findings. Further
research is needed.

-ODD subscale
changes were -2.7±4.1
with the atomoxetine
treated subjects
(overall decrease in
symptom severity)
-At least 25%, 30%, or
40% improvement in
ADHD subscale scores
-45.8% of atomoxetine
group reported nausea,
vomiting, and

-Potential for bias
because the
researchers work for
or are affiliated with
the sponsor of the
study: Eli Lilly Italy
-Due to the duration
there is no way to tell
whether atomoxetine
beneficial effects will
persist over time

Bangs et al.,
(2008).
Pediatrics,
121(2),
e314-20.

8 weeks

Atomoxetine
-Mean final
dose: 1.2 ± 0.28
mg/kg per day
-Mean
maximum dose:
1.52 ± 0.54
mg/kg per day

131 subjects
-6 – 12
-ADHD (any subtype)
with comorbid ODD as
primary diagnosis
according to DSM-IV
criteria
-SNAP-IV ADHD
subscale score ≥ 15 at
both visits 1 and 2.
-Clinical Global
Impressions-Severity
Scale score ≥ 4 at both
visits 1 and 2.
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abdominal pain
-43% of atomoxetine
group reported
anorexia/decreased
appetite
-3 atomoxetine treated
subjects did not
complete the study due
to adverse effects
-There was a small
decrease in body
weight and less height
gain in atomoxetine
treated subjects.
However, nothing of
significance.
-Effective at
controlling ODD
symptoms at weeks 2
and 5 but no significant
difference at week 8.
-More decreased
appetite, nausea,
fatigue.
-Increased diastolic
blood pressures and
increased amount of
weight loss.

-No evidence
atomoxetine would
decrease ODD
symptom would
improve in absence of
comorbid ADHD
-Not possible to
predict if reduced
ODD symptom
effects would last
-Improvements seen
in weeks 2 and 5
could have been due
to sedation effects
-Allowing children
with anxiety and
dysthymic disorders

Hazell &
6 weeks
Stuart.
(2003).
Journal of
the American
Academy of
Child &
Adolescent
Psychiatry,
42(8), 886894. doi:
10.1097/01.
CHI.000004
6908.27264.
00

Clonidine
-0.20 mg/day
(n=25)
-0.15 mg/day
(n=4)
-0.10 mg/day
(n=6)

67 subjects
-6 – 14
-White
-Treated for minimum of
3 months with either
methylphenidate or
dexamphetamine
-Attended clinics
supervised by authors
-IQ ≥ 70
-History of normal
cardiac function

24

may have interfered
with effectiveness of
atomoxetine because
these individuals
struggled more.
-For subjects treated
-Small sample size
with clonidine, there
-Validity and
was an increased
generalizability of the
reduction in Conduct
findings to a larger
and Hyperactivity
population may be
Index Scores
limited due to the
-Conners Parent Rating small sample size and
subscale scores showed the allowance of
a 25% improvement in children with anxiety
the clonidine treated
and below normal
subjects
intellectual function
-Side effects of
to participate
concurrent
-A plethora of parents
psychotropic
were able to correctly
medication decreased
guess whether their
in Clonidine treated
child was getting
patients
clonidine or a placebo
-Symptom such as
which may have led
irritability, prone to
to bias
crying, and anxiety
-Duration too short to
were decreased with
determine lasting
the clonidine treated
benefits
group
-No ECG data was
-Drowsiness and
collected
dizziness were the two
main physical adverse
effects

Spencer et
al., (2006).
Clinical
Theraputics,
28(3), 402418.

4 weeks

Mixed
amphetamine
salts extended
release (MAS
XR) (Adderall
XR)
-10 mg (n=60),
--20 mg (n=58)
-30 mg (n=69)
-40 mg (n=61)

308 subjects
- 6 – 17
-ODD with or without
comorbid ADHD
-Normal blood pressure
and electrocardiographic
reading
-No additional illness that
could interfere with the
effectiveness and safety
of MAS XR

Gadow et al.,
(2008).
Journal of
Child
Neurology,
23(9), 981990.

2 weeks

Methylphenidat
e (Novartis
Brand RitalinIR)
-0.1 mg/kg, 4.5
mg
-0.3 mg/kg, 9.3
mg
-0.5 mg/kg,
14.3 mg

31 subjects
- 6 – 12
-Met DSM-IV criteria for
ODD, ADHD and either
Tourette’s or chronic
multiple tic disorder.
-Previously part of a
placebo-controlled,
double-blind study of
safety and efficacy of
methylphenidate in
school-age children with
chronic tic disorder.

25

-Effective in
decreasing from
baseline ODD severity
with MAS XR 30 mg/d
and MAS XR 40 mg/d
-MAS XR adverse
effects: anorexia
(25.3%), insomnia
(19.5%), headache
(18.5%), abdominal
pain (10.7%)
-1.1 to 3.5 pound
decrease in body
weight in MAS XR
groups
-Mother and teacher
ratings showed
reduction in ODD
symptom severity
-Increase in heart rate
and systolic blood
pressures directly
proportional to increase
in methylphenidate
dosage.

-Shorter duration
-Dosages were not
titrated to achieve
optimal effects
-Low baseline ODD
subscale scores (less
severe ODD
symptoms)

-Short duration
-The cause of ODD
and ADHD in
individuals with tic
disorders is unknown,
therefore response to
medication may differ
in children without a
tic disorder
-Rating scales
completed by mothers
are less effective at
measuring severity of
oppositional behavior
at home.
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